Areas under the curve (AUCs) of receiver operating characteristic analyses of DAREA, DAS28, SDAI and CDAI when used as tests for radiographic progression (defined as change of psoriatic arthritis (PsA) modified van der Heijde–Sharp score >0 at week 54; IMPACT 2 data set)
| Trial arm | Change from baseline (0) to week xx | AUC DAREA | AUC DAS28 | AUC SDAI | AUC CDAI |
|---|---|---|---|---|---|
| Infliximab | 0–54 | 0.74 | 0.74 | 0.73 | 0.72 |
| Placebo | 0–54 | 0.50 | 0.51 | 0.53 | 0.43 |
| Infliximab | 0–24 | 0.80 | 0.78 | 0.77 | 0.77 |
| Placebo | 0–24 | 0.43 | 0.48 | 0.47 | 0.42 |
CDAI, clinical disease activity index; DAREA, ‘Disease Activity index for REactive Arthritis’; DAS28, disease activity score using 28 joint counts; IMPACT 2, Infliximab Multinational Psoriatic Arthritis Controlled Trial 2; SDAI, simplified disease activity index.